• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: AV-TEMECULA-CT ABSORB GT1 BIORESORBABLE VASCULAR SCAFFOLD SYSTEM; BIORESORBABLE DRUG ELUTING SCAFFOLD

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

AV-TEMECULA-CT ABSORB GT1 BIORESORBABLE VASCULAR SCAFFOLD SYSTEM; BIORESORBABLE DRUG ELUTING SCAFFOLD Back to Search Results
Catalog Number 1234300-28
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Intimal Dissection (1333); Thrombosis (2100)
Event Date 08/08/2016
Event Type  Injury  
Manufacturer Narrative
(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.Concomitant product: stent: 3.0 x 12mm xience; scaffold: absorb gt1 3.0 x 23 mm.The absorb gt1 3.0 x 23 mm referenced is being filed under a separate manufacturer report number.The scaffold remains in the patient.Investigation is not yet complete.A follow-up report will be submitted with all additional relevant information.
 
Event Description
It was reported that the procedure on (b)(6) 2016 was to treat a moderately calcified lesion in the mid left anterior descending artery.Pre-dilatation was performed with a 2.5 x 20 mm balloon and two absorb gt1 scaffolds (3.0 x 23mm, 2.5 x 23 mm) were implanted overlapping at 14 atmospheres (atm).Post-dilatation was done with a 3.0 x 20 mm balloon at 18 atm at which time a dissection occurred at the proximal edge of the proximal 2.5 x 23 mm scaffold.A 3.0 x 12 mm xience stent was implanted overlapping part of the proximal scaffold.The patient returned on (b)(6) 2016.Optical coherence tomography (oct) did not show any malposition, but thrombus was found in the scaffolded area.A xience prox stent was implanted for treatment.No additional information was provided.
 
Manufacturer Narrative
(b)(4).There was no reported device malfunction and the product was not returned as the scaffold remains in the anatomy.A cine was received and reviewed by an abbott vascular clinical specialist who concluded: documented thrombosis present in the lad of two previously deployed absorb scaffolds with a patent proximal metallic stent.Vessel is re-treated with two metallic stents.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effects of angina, dissection and thrombosis, as listed in the bioresorbable vascular scaffold (bvs) system, absorb, instructions for use (ifu) are known adverse events associated with the use of a coronary scaffold in native coronary arteries.Based on the case information and related record review, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to design, manufacture or labeling of the device.
 
Event Description
Subsequent to the previously filed medwatch report, there was a correction to the event: the patient presented with a st elevated myocardial infarction.The first scaffold implanted was a 2.5 x 23 mm absorb, not an absorb gt1 as initially reported.A 3.0 x 28 mm absorb gt1, (not a 3.0 x 23 mm as initially reported), was implanted proximally.The dissection occurred at the proximal end of this scaffold.The patient returned due to angina.Timi 3 flow was restored after the thrombosis was treatment with the xience prox stent.There was a good final patient outcome it was confirmed that the patient had been compliant with dual antiplatelet drug therapy (dapt) of aspirin and prasugrel.No additional information was provided.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ABSORB GT1 BIORESORBABLE VASCULAR SCAFFOLD SYSTEM
Type of Device
BIORESORBABLE DRUG ELUTING SCAFFOLD
Manufacturer (Section D)
AV-TEMECULA-CT
abbott vascular
26531 ynez road
temecula CA 92591 4628
Manufacturer (Section G)
ABBOTT VASCULAR, TEMECULA, CA USA REG# 2024168
abbott vascular
26531 ynez road
temecula CA 92591 4628
Manufacturer Contact
connie speck
abbott vascular
26531 ynez road
temecula, CA 92591-4628
9519143996
MDR Report Key6201388
MDR Text Key63175763
Report Number2024168-2016-09211
Device Sequence Number1
Product Code PNY
Combination Product (y/n)N
Reporter Country CodeGM
PMA/PMN Number
P150023
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Health Professional
Remedial Action Other
Type of Report Initial,Followup
Report Date 02/06/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/22/2016
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date05/21/2017
Device Catalogue Number1234300-28
Device Lot Number5112461
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received02/02/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured11/01/2015
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
-
-